日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Inpatient Hepatitis C Treatment Coordination and Initiation for Patients Who Inject Drugs

注射吸毒患者的住院丙型肝炎治疗协调与启动

McCrary, L Madeline; Roberts, Kate E; Bowman, Mary Catherine; Castillo, Briana; Darling, Jama M; Dunn, Christine; Jordan, Robyn; Young, Jane E; Schranz, Asher J

A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study

一项关于口服抗病毒药物治疗慢性丙型肝炎的实用性随机对照试验:PRIORITIZE 研究

Sulkowski, Mark S; Moon, Juhi S; Sherman, Kenneth E; Morelli, Giuseppe; Darling, Jama M; Muir, Andrew J; Khalili, Mandana; Fishbein, Dawn A; Hinestrosa, Federico; Shiffman, Mitchell L; Di Bisceglie, Adrian; Rajender Reddy, K; Pearlman, Brian; Lok, Anna S; Fried, Michael W; Stewart, Paul W; Peter, Joy; Wadsworth, Summer; Kixmiller, Scott; Sloan, Anquenette; Vainorius, Monika; Horne, Patrick M; Michael, Larry; Dong, Meichen; Evon, Donna M; Segal, Jodi B; Nelson, David R

A Quality Improvement Initiative Results in Improved Rates of Timely Postvariceal Bleeding Surveillance Endoscopy

一项质量改进计划提高了及时进行静脉曲张后出血监测内镜检查的比例。

Moon, Andrew M; Kim, Hannah P; Barritt, A Sidney 4th; Darling, Jama; Arora, Shifali

An Interaction Between Glecaprevir, Pibrentasvir, and Colchicine Causing Rhabdomyolysis in a Patient With Chronic Renal Disease

格卡瑞韦、哌仑他韦和秋水仙碱相互作用导致慢性肾病患者发生横纹肌溶解症

Harrison, Dawn S; Giang, Jane; Darling, Jama M

Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET Analysis

肝细胞癌的治疗状态不影响持续病毒学应答率:一项 HCV-TARGET 分析

Radhakrishnan, Kavita; Di Bisceglie, Adrian M; Reddy, K Rajender; Lim, Joseph K; Levitsky, Josh; Hassan, Mohamed A; Darling, Jama M; Feld, Jordan J; Akushevich, Lucy; Vainorius, Monika; Nelson, David R; Fried, Michael W; Brown, Robert S Jr; Terrault, Norah A

Daclatasvir and sofosbuvir treatment of decompensated liver disease or post-liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real-world cohort

在真实世界队列研究中,达卡他韦和索非布韦治疗失代偿性肝病或肝移植后丙型肝炎病毒复发的晚期肝病/肝硬化患者

Kwo, Paul; Fried, Michael W; Reddy, K Rajender; Soldevila-Pico, Consuelo; Khemichian, Saro; Darling, Jama; Zamor, Phillippe J; Napoli, Andrew A; Anduze-Faris, Beatrice; Brown, Robert S Jr

Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection

西美普韦联合索非布韦(加或不加利巴韦林)治疗HCV基因1型感染的真实世界疗效

Sulkowski, Mark S; Vargas, Hugo E; Di Bisceglie, Adrian M; Kuo, Alexander; Reddy, K Rajender; Lim, Joseph K; Morelli, Giuseppe; Darling, Jama M; Feld, Jordan J; Brown, Robert S; Frazier, Lynn M; Stewart, Thomas G; Fried, Michael W; Nelson, David R; Jacobson, Ira M

High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV-infected patients regardless of DPP4 activity.

无论 DPP4 活性如何,HCV 感染患者血浆中 MIG (CXCL9) 水平高有利于对聚乙二醇干扰素和利巴韦林产生反应

Johansson Susanne, Talloen Willem, Tuefferd Marianne, Darling Jama, Fanning Gregory, Fried Michael W, Aerssens Jeroen

Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response.

治疗前血清干扰素-γ诱导蛋白-10的定量分析提高了IL28B基因多态性对丙型肝炎治疗反应的预测价值

Darling Jama M, Aerssens Jeroen, Fanning Gregory, McHutchison John G, Goldstein David B, Thompson Alexander J, Shianna Kevin V, Afdhal Nezam H, Hudson Michael L, Howell Charles D, Talloen Willem, Bollekens Jacques, De Wit Mieke, Scholliers Annick, Fried Michael W

New and Evolving Management Paradigms for Hepatitis C after Liver Transplantation

肝移植后丙型肝炎管理模式的新兴与演变

Barritt, A Sidney 4th; Darling, Jama M; Hayashi, Paul H